Evidence map›Paper›PMID 42093888›Full record

ArticleFrontiers in pharmacology2026

A dihydrofuro[2,3-b] benzofuran derivative alleviates lipopolysaccharide induced acute lung injury

Yuxi Wang, Zeping Shan, Shenyan Shao, Yuanyuan Yang, Aijing Zhang, Guimei Wang, Xiaohong Wu, Yuqing Cai, Chengyun Xu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yuxi Wang *Department of Respirology, Hangzhou Lin'an Traditional Chinese Medicine Hospital, Affiliated Hospital, Hangzhou City University, Hangzhou, China.
Zeping Shan *Department of Pharmacology, Hangzhou City University School of Medicine, Hangzhou, China.
Shenyan ShaoDepartment of Pharmacology, Hangzhou City University School of Medicine, Hangzhou, China.
Yuanyuan YangDepartment of Pharmacology, Hangzhou City University School of Medicine, Hangzhou, China.
Aijing ZhangDepartment of Pharmacology, Hangzhou City University School of Medicine, Hangzhou, China.
Guimei WangDepartment of Respirology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Xiaohong WuDepartment of Respirology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Yuqing CaiDepartment of Respirology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Chengyun XuDepartment of Respirology, Hangzhou Lin'an Traditional Chinese Medicine Hospital, Affiliated Hospital, Hangzhou City University, Hangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Methods: A series of rhodomentosone-like compounds were screened in LPS-stimulated RAW264.7 macrophages for Results: QFM-3m significantly inhibited LPS-induced Conclusion: QFM-3m, a novel dihydrofurobenzofuran derivative derived from

Indexed as

acute lung injuryanti-inflammatory activitydihydrofurobenzofuran derivativesMAPK signalingRhodomyrtus tomentosa

Identifiers

PMID42093888
PMCPMC13139021

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.